Greenwich LifeSciences Receives UK Regulatory Approval To Expand FLAMINGO-01 Phase III Trial With Royal Marsden Collaboration

Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an

HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69

HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $50 to $69.

Greenwich LifeSciences shares are trading lower after the company provided clinical updates on FLAMINGO-01.